Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Kezar Life Sciences Inc (KZR)

Kezar Life Sciences Inc (KZR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Karora Announces Agreement with Kalamazoo Resources to Unlock Lithium Exploration Value Through Creation of Kali Metals Limited Newswire.ca - Mon May 8, 2023

/CNW/ - Karora Resources Inc. (TSX: KRR) ("Karora" or the "Corporation") is pleased to announce it has entered into an agreement with Kalamazoo Resources...

KZR.AX : 0.085 (unch)
KZR : 0.5769 (+1.21%)
KRR.TO : 6.13 (+0.08%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire - Wed Apr 5, 2023

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that...

KZR : 0.5769 (+1.21%)
Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update Business Wire - Tue Mar 14, 2023

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial...

KZR : 0.5769 (+1.21%)
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023 Business Wire - Mon Mar 13, 2023

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the...

KZR : 0.5769 (+1.21%)
Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023 Business Wire - Mon Mar 6, 2023

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will...

KZR : 0.5769 (+1.21%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire - Fri Mar 3, 2023

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that...

KZR : 0.5769 (+1.21%)
Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference Business Wire - Wed Mar 1, 2023

Kezar Life Sciences, Inc . (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen...

KZR : 0.5769 (+1.21%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire - Mon Feb 6, 2023

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that...

KZR : 0.5769 (+1.21%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire - Fri Jan 13, 2023

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that...

KZR : 0.5769 (+1.21%)
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference Business Wire - Wed Jan 4, 2023

Kezar Life Sciences, Inc . (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John...

KZR : 0.5769 (+1.21%)

Barchart Exclusives

The Spring Doldrums in The Gold Market May Be Changing Soon Barchart - 12 minutes ago
Over the past five years, data shows distinct patterns in the seasonality of gold prices. September has consistently been weak, with prices often closing lower than they opened, suggesting a decrease in market confidence or a shift in investment focus. In contrast, due to increased buying, July has shown a higher probability of gold prices closing above their opening mark. Are the Spring doldrums in gold prices ready to change to higher prices? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot